• 제목/요약/키워드: Extrapyramidal symptoms

검색결과 43건 처리시간 0.027초

섬망의 치료에 대한 Quetiapine과 Haloperidol의 전향적 개방형 연구 (A Prospective and Open-Label Trial of Quetiapine and Haloperidol in the Treatment of Delirium)

  • 최학규;박병선;이현정;최진숙;조경형;신영민
    • 정신신체의학
    • /
    • 제13권2호
    • /
    • pp.85-94
    • /
    • 2005
  • 연구목적 : 본 전향적 개방형 연구는 섬망에 대한 quetiapine과 haloperidol의 효과와 안전성을 평가하기 위하여 시행되었다. 방법: DSM-lV에 의하여 섬망으로 진단된 40명(quetiapine군 19 : haloperidol군 21)을 대상으로 순차적으로 quetiapine과 haloperidol을 투여하였다. 약물의 1차적 효과를 평가하기 위하여 한국판 섬망 평가 척도를 매일 일주일간 시행하고, 약물에 의한 2차적 효과와 안전성을 평가하기 위해 전반적 임상 인상-심각도, 한국판 간이정신상태검사, 약물에 의한 추체외로 증상 평가 척도를 각각 연구 시작시와 7일째에 시행하였다. 자료의 수집은 2004년 11월부터 2005넌 6월까지 이루어졌다. 결과: 연구 기간 동안 두 군 모두 한국판 섬망 평가 척도의 점수가 유의하게 감소하였으며, 두 군간의 평균 척도점수는 유의한 차이가 없었다. 두 약물에 대한 치료 반응율에서도 유의한 차이가 없었다. 연구 기간 동안 임상적으로 심각하거나 위험한 부작용은 관찰되지 않았다. 결론: 본 연구 결과 섬망의 치료에 있어서 quetiapine은 haloperidol과 대등한 효과와 안전성을 보였다. 기존의 연구에서 haloperidol은 장기 복용시 운동성 부작용을 유발할 가능성이 크다고 알려져 있으므로, 그러한 부작용이 적다고 알려진 quetiapine이 장기간 지속될 수 있는 섬망의 치료에 있어 haloperidol을 대체할 수 있을 것으로 기대된다.

  • PDF

조현병 환자에서 장기지속형 항정신병 주사제 팔리페리돈 팔미테이트의 효능과 안전 : 24주 개방형 연구 (Safety and Effectiveness of Long Acting Injectable Antipsychotic Paliperidone Palmitate Treatment in Schizophrenics : A 24-Week Open-Label Study)

  • 강현구;함웅;손인기;백인호
    • 생물정신의학
    • /
    • 제20권3호
    • /
    • pp.111-117
    • /
    • 2013
  • Objectives We investigated the effectiveness and safety when treated in schizophrenics with paliperidone palmitate, a long acting injectable antipsychotic. Methods This was a 24-week open-label study, performed at one center in Korea. The eligible patients with schizophrenia diagnosed by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria were enrolled. Patients received long-acting paliperidone palmitate injection (234 mg, baseline; 156 mg, week 1 ; then once 4 weeks flexible dosing). Effectiveness assessments were measured by the Positive and Negative Syndrome Scale (PANSS), The Clinical Global Impression Severity Scale (CGI-S), The Personal and Social Performance (PSP) at baseline, week 1, every 4 weeks untill 24 weeks or endpoint. Safety assessments were measured by The Extrapyramidal Symptom Rating Scale (ESRS), body weight (BW) and incidence of adverse events. Oral antipsychotics were stopped or tapered off within next 14 days. Results Of 20 patients recruited, 9 patients (45%) completed the study. Paliperidone palmitate produced a significant improvement in PANSS total score from baseline to endpoint. The response rate was 75% [mean change (${\pm}SD$) $-25.9{\pm}14.4$, all p < 0.001]. The CGI-S and PSP total scores significantly improved during 24 weeks (All p < 0.001). Eighty percent of patients reported adverse events and most common adverse events (${\geq}10%$) in paliperidone palmitate were anticholinergic adverse event, extrapyramidal symptoms, weight gain, akathisia, insomnia, headache, agitation, anxiety and GI trouble. ESRS score is not statistically significant, but tends to get better at the end of the study when compared to baseline. Conclusions Our study results demonstrated maintained effectiveness and safety of paliperidone palmitate treatment in schizophrenics. And provides both clinicians and patients with a new choice of treatment that can improve the outcome of long term therapy. Their potential effectiveness and safety should be better addressed by future randomized-controlled trials.

소아 청소년 정신과 입원 환자에서 Risperidone의 효과 및 안정성에 관한 연구 (THE EFFICACY AND SAFETY OF RISPERIDONE IN CHILD & ADOLESCENT PSYCHIATRIC INPATIENT)

  • 박정현;김붕년
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제16권2호
    • /
    • pp.239-250
    • /
    • 2005
  • 목적 : 소아 청소년 정신과 환자에서 비전형 항정신병약물인 risperidone에 대한 효과 및 안전성에 대한 자료를 얻고자 하였다. 방법 : 2001년 1월에서 2002년 6월까지 서울대병원 소아 청소년 정신과 병동에 입원한 환자 중 risperidone이 사용되었던 5.4세에서 17.3세 사이의 환자 31명(남 18, 여 : 13)을 대상으로 후향적인 진료기록지 검토를 시행하였다. 결과 : Risperidone이 사용된 주된 정신과 진단은 정신분열병 및 기타 정신증, 정신병적 증상이 동반된 I형 양극성 장애, 뚜렛장애, 자폐스펙트럼 질환, 혼합형 표현성 및 수용성 언어장애, 주의력결핍 과잉행동장애 및 품행장애, 강박장애 등이었으며 이 중 12명에서 정신지체가 동반되었다. Risperidone사용의 주된 목표 증상은 정신병적 증상(n=13, $41.9\%$), 공격성, 충동성, 과잉행동, 상동증 등과 같은 행동 증상(n=10, $32.3\%$), 만성적이고 심한 틱 증상 (n=8, $25.8\%$)이었다. Risperidone의 효과는 risperidone의 목표 증상에 대한 CGI(Clinical Global Improvement)로 평가되었는데 $67.7\%$에서 중등도 이상의 호전을 보였고 평균 7.5개월 동안 치료효과가 유지되었다. Risperidone의 평균 하루 사용량은 $0.05{\pm}0.1mg/kg$이었으며, 정신병적증상군이 0.07mg/kg로 다른 두 증상군(0.04mg/kg)에 비해 의미 있게 높았다. 부작용으로는 체중증가(n=23)가 가장 흔하였으며 그 외 추체외로계 증상(n=15), 자율신경계증상(n=6), 진정작용(n=5), 고프로락틴혈증(n=2) 등 다양한 부작용이 보고되었다. 그러나 부작용으로 인해 약물을 변경한 경우는 없었으며 외래 마지막 방문 시 $90\%$에서 risperidone을 유지하고 있어 약물내약성은 비교적 우수한 것으로 평가되었다. 결론 : 비전형 항정신병 약물인 risperidone은 정신병적 증상, 공격성, 충동성, 과잉행동, 상동행동을 포함하는 행동증상, 만성적이고 심각한 틱증상 등 다양한 소아 청소년 정신병리의 치료에 비교적 안전하고 효과적인 약물이 될 수 있을 것으로 평가된다. 향후 risepridone의 효과 및 안전성에 대한 보다 장기적이고 체계적인 연구가 필요할 것이다.

  • PDF

Wilson 병의 진단시 임상 발현 양상에 대한 고찰 (The Study of the Initial Presentations of Wilson Disease at Diagonosis)

  • 양태진;지근하;송민섭;황태규
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제4권2호
    • /
    • pp.199-206
    • /
    • 2001
  • 목적: 윌슨병으로 진단 받은 환자들의 진단 당시의 임상 양상의 분포, 발병 연령과 검사 소견들을 파악하고, 또한 초기 발견의 중요성을 고찰하고자 본 연구를 시행하였다. 방법: 1990년 1월부터 10년간 부산 백병원에 입원하여 윌슨병으로 진단 받은 환자 20례를 대상으로 진단 당시의 증상과 증상 발현시기, 진단까지의 기간, 검사 소견 등을 후향적으로 조사하였다. 결과: 20명의 환자들 중에 간 증상 단독 발현은 12명(60%), 그 중 2명은 우연히 AST/ALT가 증가된 것을 발견한 경우였으며, 신경 증상 단독 발현은 2명(10%), 신경 정신증상과 간 증상이 같이 나타난 경우는 4명(20%), 혈액 증상이 주된 경우 1명(5%), 그리고 증상이 없으며 AST/ALT도 정상이나 가족 검진에서 혈중 ceruloplasmin이 감소된 것을 발견한 경우가 1명(5%) 있었다. 모든 환자들에게서 혈중 ceruloplasmin의 농도는 유의하게 낮았다. 가족력은 5례에서 있었다. 간 증상은 진단시 이미 간경화로 진행한 것을 초음파로 진단한 경우가 12명(60%)이었으며, 이 중 2명이 진단 후 1년 내에 사망하였다. 결론: 윌슨병은 빠른 진단과 치료가 중요하다. 그러나 다른 유전성 대사질환들과는 달리 전체 신생아의 선별검사는 의미가 없으며, 환자가 있는 가족에서 혈중 ceruloplasmin과 소변 내 구리, 간 효소 수치와 각막을 검사하는 것이 좋다. 소아기에 간염의 증상이나 지속적으로 증가된 간 효소 수치를 보일 때 또는 가족 중에 원인이 밝혀지지 않은 간질환의 가족력이 있을 때에는 윌슨병을 의심해 보아야 하겠다. 또한 청소년기 이후에 추체외로 증상이나 소뇌 증상 등 운동 신경계의 증상을 호소하든지 혈액 이상, 소변 검사상 이상이 복합적으로 나타나는 경우 등에서도 혈중 ceruloplasmin을 꼭 확인해 보아야 한다. 그 외에 신경 증상 및 정신 증상을 주소로 내원한 경우에도 간기능 검사를 꼭 시행해 보아야 하겠다.

  • PDF

Risperidone Monotherapy in Children and Adolescents with Autism Spectrum Disorders : A Naturalistic Study

  • Won, Eun-Kyung;Park, Jin-Park;Lee, Young-Ryul;Nam, Yoon-Young;Min, He-Ji;Kim, Yeni
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제26권4호
    • /
    • pp.273-278
    • /
    • 2015
  • Objectives : We retrospectively investigated the efficacy and tolerability of risperidone monotherapy in subjects with autism spectrum disorder (ASD). In addition, we did mixed effect model analysis of the effects of risperidone in patients with ASDs naturalistically treated in a routine clinical setting to determine whether the clinical effects were maintained and the side effects were tolerable. Methods : This retrospective study assessed children and adolescents with ASD, who were on risperidone monotherapy from July 2010 to July 2011 at the Child and Adolescent ASD Clinic at Seoul National Hospital. Outcome measures included the Clinical Global Impression-Severity of Illness (CGI-S) and the CGI-Improvement (CGI-I) scales along with other clinical indices: dosage, target symptoms, and side effects. Results : The mean dose of risperidone in 47 children and adolescents with ASD (40 males, 7 females; age range 5-19 years) who were on risperidone monotherapy was $1.6{\pm}0.8mg/day$, and the mean duration of the treatment period was $20.2{\pm}17.3months$. Aggressive behavior, stereotypic behavior, irritability, and self-injurious behavior were the most frequent target symptoms of risperidone. The most common side effects were weight gain followed by somnolence and extrapyramidal symptoms. In a mixed effects model analysis of CGI-I scores, the mean CGI-I score at the 1 month follow-up was significantly different from the mean CGI-I score of the 3-month follow-up (p=.046), and the CGI-I scores were equally maintained over 3 to 48 months [F(6, 28.9)=4.393, p=.003]. Of the 47 patients, 33 patients (70.2%) were identified as the response group, showing an end point CGI-I rating of 3 or under and having continued risperidone treatment for at least 6 months. The baseline CGI-S score showed significant association with clinical response to risperidone (p=.005), the mean baseline CGI-S was higher in the response group compared to the non-response group. Conclusion : In this study, clinical improvement of risperidone stabilized around 3 months and was equally maintained up to 48 months with tolerable side effects, supporting maintenance of risperidone treatment in children and adolescents with ASDs.

정신분열증환자에서 Nemonapride와 Haloperidol의 치료결과 및 내약성에 대한 비교분석 (Comparison of Therapeutic Efficacy and Tolerance Between Nemonapride and Haloperidol in-Schizophrenic Patients)

  • 성상경;홍광화
    • 생물정신의학
    • /
    • 제2권1호
    • /
    • pp.123-130
    • /
    • 1995
  • A single-blind comparative study was performed using haloperidol as a reference drug in order to evaluate the efficacy and safety of nemonapride, a new benzamide derivative, in sixty-nine Korean schizophrenic patients. the total period of the study was 8 weeks, maximum dosage of nemonapride was 36mg and that of haloperidol was 24mg. Psychopathology and extrapyramidal symptoms were assessed every week or four weeks until the end of the 8th week using the PANSS, BPRS, and 4 point general side effect check list, The drug safety was assessed every week until the end of the 8th week using vital sign, body weight, EEG, EKG, and blood chemistry. In total. one patient discontinued nemonapride treatment and seven patients discontinued haloperidol treatment before the end of the study. Therefore sixty-one patients(88 %) completed the study. PNASS and BPRS scores of the two groups on the end study point demonstrated a significant improvement compared with baseline score. The number of patients who had a clinical improvement of at least 20% in baseline score was similiar in both treatment groups. The difference of Simpson's rating scale socres were significant in both groups, and mean scores were more high in the haloperidol group than in nemonapride group. No significant EKG, EEG changes were induced, no relevant change in body weight or clinical laboratory parameters were observed in the sixty-one patients during 8 weeks and no Significant difference in the both groups. From these results, nemonapride is considered to be a clinically useful drug having a wide range of antipsychotic effect in schzophrenic patients.

  • PDF

올란자핀의 체중증가 부작용 발생율 및 체중변화량 (Incidence and Severity of Weight Gain Associated with the Use of Olanzapine for the Treatment of Schizophrenia)

  • 이경희;스리니바산샨무감;렌가라잔바스카란;산토쉬쿠마르나가야스리라만;용철순;최한곤;우종수;유봉규
    • 약학회지
    • /
    • 제52권4호
    • /
    • pp.288-292
    • /
    • 2008
  • Olanzapine, an atypical antipsychotic, has been widely used for the treatment of schizophrenia and bipolar disease. Although olanzapine is less associated with extrapyramidal symptoms and neuroleptic malignant syndrome compared to existing typical antipsychotics, the use of this drug has a problematic side effect of weight gain, which may cause metabolic syndrome such as type 2 diabetes. However, there are few hospitals practicing body weight monitoring of the patients on olanzapine or other atypical antipsychotics. The goal of this study was to identify the incidence and severity of weight gain associated with the use of the drug in Korea. We performed body weight monitoring of the patients who were on the drug in a hospital setting. Mean of the weight gain (as of one-month-transformation) was 4.33 and 3.39 kg for the male and female patients, respectively. The incidence in the young patients was higher than that observed in the old patients, and the severity was the highest in patients in their thirties followed by twenties or younger. This result suggests that the pattern of the weight gain associated with the use of olanzapine in Korea is similar to the reports performed and documented in US and European countries. Therefore, it appears that healthcare professionals in Korea should also watch on the weight gain issue in patients who are on olanzapine or other atypical antipsychotics.

한국인 정신분열병 환자에서 비정형 항정신병 약물의 치료반응과 체중증가의 관련성에 대한 연구 (Association between the Weight Gain and Treatment Response to Atypical Antipsychotics in Korean Patients with Schizophrenia)

  • 이재병;함병주;이화영;이민수
    • 생물정신의학
    • /
    • 제18권4호
    • /
    • pp.225-231
    • /
    • 2011
  • Objectives Atypical antipsychotics show better treatment efficacy, safety and tolerability than typical antipsychotics. Among the adverse events observed during treatment with antipsychotics, extrapyramidal syndrome (EPS) and negative symptoms has been greatly reduced. But still, weight gain is receiving growing attention. The aim of this study was to investigate the association between therapeutic response to atypical antipsychotics and weight gain in admission status. Methods The study was conducted for Korean inpatients with schizophrenia in a university hospital in Seoul, between Jan 2006 and Dec 2010. Data was collected by reviewing the medical record of 39 consecutively hospitalized patients with Schizophrenia (DSM-IV) at a university hospital. Positive and Negative Symptom Scale (PANSS), Body Mass Index (BMI) and body weights were measured. Results No significant difference was observed for sex, age, illness onset age, family history of schizophrenia, numbers of hospitalization before treatment, educational years, marriage status, occupational status and subtype of schizophrenia between weight gainers and non-weight gainers. Regarding treatment response to atypical antipsychotics, weight gainers show significantly more PANSS decrease than non-weight gainers during admission period. Conclusions Our findings suggest that it appears to be more likely to respond to atypical antipsychotics in weight gainers than non-weight gainers (that weght gainers appear to be more likely to respond to atypical antipsychotics than non-weight gainers). These results show that the antipsychotic-induced body weight gain is associated with therapeutic response of antipsychotics in Korean inpatients with schizophrenia.

Risperidone이 혈청 Prolactin 농도에 미치는 영향 (The Effect of Risperidone on Serum Prolactin Concentrations)

  • 전진숙;조웅;오병훈
    • 생물정신의학
    • /
    • 제5권2호
    • /
    • pp.253-262
    • /
    • 1998
  • Objectives : Risperidone, an atypical antipsychitics which blocks both dopaminergic and serotonergic receptors, have a good response to the negative symptoms as well as positive symptoms, and improve cognitive dysfunction of schizophrenic patients. Furthermore, it has few extrapyramidal side effects and tardive dyskinesia. Although it had been reported that the atypical antipsychotics have less effect on prolactin(PRL) than the classical antipsychotics, we could experience PRL-associated symptoms such as amenorrhea, galactorrhea and hyperprolactinemia in practice. Therefore, we tried to identify the sex differences of risperidone-induced hyperprolactinemia, to evaluate factors affecting PRL levels, and to know the association between cognitive disorders and PRL. Methods : The baseline levels of PRL and TSH prior to risperidone administration were measured by enzyme immunoassay method for 50 patients(25 ma-les and 25 females) admitted with schizophrenia, schizoaffective disorder or schizophreniform disorder according to the DSM-IV classification, and the measurements of PRL were repeated on the 2nd and the 4th wks of risperidone administration. Concomitantly, the severity of psychotic symptoms using CGI, BPRS and PANSS, and the cognitive dysfunction using PANSS-CF were assessed prior to, on the 2nd and the 4th wks of risperidone administration. The PRL and TSH levels of 54 healthy controls(29 males and 25 females) who had no medical, neurological and psychiatric illnesses were also evaluated. Furthermore, the correlation with the psychiatric diagnosis, education, age, sex, duration of illnesses, risperidone dosage, duration of risperdone administration, TSH concentration, cognitive function, severity of psychotic symptoms were also identified. Results : 1) The baseline PRL levels of female schizophrenics($74.3{\pm}49.6ng/ml$) were significantly(p<0.005) higher than those of males($36.3{\pm}24.6ng/ml$), which were significantly(p<0.0001 respectively) higher than those of controls(females $16.9{\pm}6.1ng/ml$, males $13.3{\pm}4.9ng/ml$). The PRL levels measured on the 2nd wks(females $133.7{\pm}47.8ng/ml$, males $56.9{\pm}23.6ng/ml$) and on the 4th wks(females $146.1{\pm}45.9ng/ml$, males $70.0{\pm}31.5ng/ml$) after risperidone administration were significantly(p<0.0001 respectively) higher in females. The mean dosages of risperidone on the 2nd wks were $3.8{\pm}1.7mg$(2-6mg) for the females and $4.0{\pm}1.6mg$(2-6mg) for the males, and on the 4th wks were $4.5{\pm}2.1mg$(2-8mg) for the females and $5.4{\pm}2.2mg$(2-8mg) for the males. 2) The rise of PRL levels were positively correlated with increased risperidone dosage in males(${\gamma}$=0.307 on the 2nd wks and ${\gamma}$=0.280 on the 4th wks), while they were not correlated with dosages in females. For the females, the PRL levels were negatively correlated(${\gamma}$=-0.320) with decrease of TSH concentration. The baseline PRL levels were not correlated with age, education, duration of illnesses, psychopathology, cognitive disorders in both males and females, while it was negatively correlated with TSH levels only in females(${\gamma}$=-0.320). 3) The cognitive dysfunction was not correlated with PRL levels in males, while PANSS-CF scores were negatively correlated with PRL levels(${\gamma}$=-0.220 on the 2nd wks and ${\gamma}$=-0.366 on the 4th wks) in females. The psychopathology was positively correlated with cognitive dysfunction in both males and females. Therefore, the risperidone-induced cognitive improvement seemed to be correlated with improvement of psychopathology in both males and females, and with increase in PRL levels only in females. Conclusions : The fact that the serum PRL levels of schizophrenics were higher than those of controls, especially in females suggested that it could be related with risperidone dosage in males and with primary pathological process in females. The risperidone-associated cognitive improvement seemed to be related with general improvement of psychopathology as well as the rise of PRL levels especially in females. The facts that the effect of risperidoneinduced hyperprolactinemia and the cognitive function were more in females suggested that somewhat different mechanisms could be exerted on them.

  • PDF

리스페리돈이 심혈관계에 미치는 영향 (The Cardiovascular Effect of Risperidone)

  • 최세진;전진숙;최영태
    • 생물정신의학
    • /
    • 제7권2호
    • /
    • pp.191-197
    • /
    • 2000
  • Objectives : Risperidone is a new antipsychotic drug developed to overcome the therapeutic limitation of conventional antipsychotics. It responses to negative as well as positive symptoms by blocking both dopaminergic and serotonergic receptors, causing no significant side effects such as agranulocytosis and seizure. It is, however, not known whether it induces any serious cardiovascular side effects as evoked by other conventional antipsychotic drugs. The aims of this study were to evaluate the effect of risperidone on cardiovascular function, and to discuss the factors affecting the cardiovascular function. Methods : For 42 patients(22 males and 20 females) diagnosed as schizophrenia, schizophreniform disorder or schizoaffective disorder according to the DSM-IV classification, the cardiovascular fuctions such as heart rate, systolic and diastolic blood pressure, PR interval, QRS interval and QT interval were successively checked before and after 2 weeks and 4 weeks risperidone administration. Furthermore, variables such as body weight, Brief Psychiatric Rating Scale(BPRS), Clinical Global Impression(CGI), Extrapyramidal Symptom Rating Scale(ESRS), Anticholinergic Rating Scale(ARS), serum cholesterol level, serum triglyceride level, serum high-density-lipoprotein level, serum WBC, serum Hb, serum platelet level, prothrombin time and partial thromboplastin time were also analyzed before and after 2 weeks and 4 weeks risperidone administration. Results : 1) Risperidone treatment resulted in a significantly decreased heart rate and increased QT interval after 4 weeks administration(p<0.005 respectively). 2) The scores of BPRS and CGI were significantly decreased after 2 weeks and 4 weeks risperidone administration as compared with baseline(p<0.001 respectively). The scores of ESRS and ASRS were significantly increased after 2 weeks and 4 weeks risperidone administration as compared with baseline(p<0.001 respectively). 3) There were positive correlations between heart rate after 4 weeks and total dose(P<0.05). Blood pressure was significantly(p<0.05) correlated with sex(higher in male) and significantly(p<0.05) positive correlated with body weight. QT interval was significantly(p<0.05) correlated with sex(longer in female) and smoking history(shorter in smokers). Conclusions : Risperidone could induce significant change in heart rate and Q-T interval. Therefore, the cardiovascular safety for risperidone should be reconsidered according to the duration and dosage increase.

  • PDF